Key Insights:
- Novavax's (NVAX, Financial) stock surged by 23% after an FDA request for more data on its COVID-19 vaccine.
- Analyst consensus suggests a significant potential upside, with a one-year price target averaging $17.33.
- GuruFocus estimates a GF Value of $5.64, indicating a potential downside of 23.37% from the current price.
Novavax Inc. (NVAX) experienced a substantial 23% increase in its stock price recently, driven by the U.S. Food and Drug Administration's (FDA) request for further clinical data concerning its COVID-19 vaccine. This development arises as discussions continue about the vaccine's approval status, which has been authorized for emergency use since 2022 but has encountered scrutiny over its single-antigen formulation.
Wall Street Analysts Forecast
According to projections from six financial analysts over the next year, the average price target for Novavax Inc. (NVAX, Financial) stands at $17.33. This projection includes a high estimate reaching $25.00 and a low estimate at $9.00—indicating a significant potential upside of 135.51% from the current trading price of $7.36. Investors can explore more extensively detailed estimates on the Novavax Inc (NVAX) Forecast page.
Currently, Novavax Inc. (NVAX, Financial) holds an "Outperform" status based on the average brokerage recommendation from seven firms, with an overall rating of 2.3 on a scale from 1 (Strong Buy) to 5 (Sell), reflecting a positive sentiment towards the company.
GF Value Estimation
According to GuruFocus estimates, the projected GF Value for Novavax Inc (NVAX, Financial) in the upcoming year is pegged at $5.64. This estimation suggests a potential downside of 23.37% from its current price of $7.36. The GF Value is calculated by analyzing historical trading multiples, past business growth, and anticipated future performance. For more comprehensive data, visit the Novavax Inc (NVAX) Summary page.
